Study of Denosumab for Prevention of Skeletal Disease Progression in Children With Fibrous Dysplasia

Fibrous Dysplasia Clinical Trial

Official title:

A Phase 2 Study of Denosumab for Prevention of Skeletal Disease Progression in Children With Fibrous Dysplasia

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05419050
• Other study ID #: 10000780
• Secondary ID: 000780-D
• Status: Recruiting
• Phase: Phase 2
• Start date: October 12, 2022
• Est. completion date: June 1, 2024

Study information

• Verified date: March 29, 2024
• Source: National Institutes of Health Clinical Center (CC)
• Contact: Alison M Boyce, M.D.
• Phone: (301) 827-4802
• Email: alison.boyce[@]nih.gov
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Background: Fibrous dysplasia (FD) is a disease that affects the bones. It causes bone lesions that can become weak and lead to fractures, deformity, and nerve injuries. FD bone lesions begin to develop soon after birth and grow during childhood. The lesions stop growing in adults but can still cause disability. Researchers want to find ways to stop the growth of FD bone lesions. Objective: To test a study drug (denosumab) in children with FD. Eligibility: Children aged 4 to 14 years with FD and who are also enrolled in the Screening and Natural History protocol (98-D-0145). Design: Participants will have a screening visit at the NIH clinic or by telehealth. Their medical history will be reviewed. Participants will stay overnight in the hospital 4 times in 76 weeks. Each stay will last 5 to 7 nights. Participants will also visit a local lab for blood and urine tests every 4 weeks during the study. Participants will receive denosumab once every 4 weeks for 48 weeks. The medication is given as a shot injected under the skin using a small needle. Some injections may be performed at home by a caregiver. The caregiver will receive training for this procedure. Participants will undergo many tests that may be repeated throughout the study. They will have a dental exam. They will have tests of their strength and ability to move freely. They will have x-rays and other scans to get pictures of their bones. Participants will be given another medicine that is administered through a needle in the arm over 30 minutes.

Description:

Study Description: This will be a phase 2, open label, single arm study of denosumab treatment to prevent fibrous dysplasia (FD) lesion progression in children. Objectives: Primary Objective: Evaluate the effect of denosumab on FD lesion progression in children. Secondary Objectives: - Evaluate the effects of denosumab on FD lesion activity. - Evaluate the effect of denosumab on strength and mobility. - Evaluate the effect of denosumab on pain and quality of life. - Evaluate the safety and tolerability of denosumab in children with FD. Endpoints: Primary Endpoint: Change in Skeletal Burden Score from baseline to 48 weeks Secondary Endpoints: - Percent change in serum bone turnover markers from baseline to 48 weeks: Procollagen 1 Intact N-Terminal Propeptide (P1NP, formation marker), C- telopeptides (CTX, resorption marker), osteocalcin, and bone-specific alkaline phosphatase - Change in 18F-NaF PET/CT total lesion activity from baseline to 48 weeks - Change in 18F-NaF PET/CT sentinel lesion intensity (SUVmax) from baseline to 48 weeks - Change in functional parameters from baseline to 48 weeks, including muscle strength, range-of-motion, and walking speed - Change in patient-reported outcome scales evaluating pain and quality of life from baseline to 48 weeks, including PROMIS Pediatric measures of Pain Intensity, Pain Interference, Mobility, and Fatigue.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 15
• Est. completion date: June 1, 2024
• Est. primary completion date: June 1, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 4 Years to 14 Years

Eligibility

• INCLUSION CRITERIA:

In order to be eligible to participate in this study, an individual must meet all of the

following criteria:

• Confirmed diagnosis of fibrous dysplasia
• Age 4 to 14 years
• Concurrent enrollment in the companion Screening and Natural History protocol 98-D-0145
• Provision of signed and dated informed consent form
• Stated willingness of guardian/Legally Authorized Representative (LAR) to comply with all study procedures and availability for the duration of the study
• Ability of guardian/LAR to understand and the willingness to sign a written informed consent document
• For females of reproductive potential: agreement to use highly effective contraception

for during study participation. Highly effective contraception methods include:

• Total abstinence. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.
• Combination of the following (a+b or a+c, or b+c):
• Use of oral, injected or implanted hormonal methods of contraception or other forms of hormonal contraception that have comparable efficacy (failure rate <1%), for example hormone vaginal ring or transdermal hormone contraception
• Placement of an intrauterine device (IUD) or intrauterine system (IUS)
• Barrier methods of contraception: Condom or Occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/vaginal suppository
• For males of reproductive potential: use of condoms or other methods to ensure effective contraception with partner
• Minimum body weight of 12 kilograms EXCLUSION CRITERIA: An individual who meets any of the following criteria will be excluded from participation

in this study:

• Pregnancy or lactation
• Known allergic reactions to denosumab
• Prior history, or current evidence, of osteomyelitis/osteonecrosis of the jaw
• Planned invasive dental procedure for the course of the study
• Presence of non-healed dental or oral surgery
• Orthopedic procedure performed less than 6-weeks prior to first day of the denosumab administration (Day 0)
• Acute fracture less than 6-weeks prior to first day of the denosumab administration (Day 0)
• Serum calcium or albumin-adjusted serum calcium below the normal range for the NIH laboratory (patients will be eligible for re-screening after a repletion period lasting up to 6 months)
• 25-hydroxyvitamin D level than 20 ng/mL (patients will be eligible for re screening after a repletion period lasting up to 6 months)
• Untreated or inadequately treated hypophosphatemia as determined by the principal investigator (patients will be eligible for re-screening after initiation or optimization of phosphorus replacement no longer than 6 months)
• Inability to comply with a non-sedated 18F-NaF PET/CT (subjects will be eligible for re- screening after 6 months)
• Use of another investigational agent within the last 3 months prior to the first day of the denosumab administration (Day 0)
• Have any condition which in the opinion of the PI could present a concern for subject safety or difficulty with data interpretation.

Related Conditions & MeSH terms

• Disease Progression
• Fibrous Dysplasia
• Fibrous Dysplasia of Bone

Intervention

Drug:
• denosumab
monoclonal antibody to receptor activator of nuclear kappa-B ligand (RANKL), a protein involved in regulating osteoclastogenesis

Locations

Country	Name	City	State
United States	National Institutes of Health Clinical Center	Bethesda	Maryland

Sponsors (1)

Lead Sponsor	Collaborator
National Institute of Dental and Craniofacial Research (NIDCR)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Skeletal Burden Score	Skeletal Burden Score is a validated measure for quantifying FD disease burden shown to correlate with skeletal outcomes	48 weeks
Secondary	Percent change in serum bone turnover markers from baseline to 48 weeks: procollagen 1 propeptide (P1NP, formation marker), beta crosslaps telopeptides (CTX, resorption marker), osteocalcin, and bone-specific alkaline phosphatase	reflect underlying bone turnover, and correlate with skeletal outcomes	48 weeks
Secondary	Adverse events	Safety endpoints for expected and unexpected adverse events	76 weeks
Secondary	Change in functional parameters: - Muscle strength - Range-of-motion - Walking speed (6-minute walk)	Outcome measures that reflect activities of daily living	48 weeks
Secondary	Change in 18F-NaF PET/CT total lesion activity from baseline to 48 weeks	reflect underlying lesion activity and correlate with skeletal outcomes	48 weeks
Secondary	Change in patient-reported outcome scales: - SF10 - Brief Pain Inventory - Brief Fatigue Inventory	Outcome measures to determine pain and quality of life	48 weeks
Secondary	Change in 18F-NaF PET/CT sentinel lesion intensity (SUVmax)	reflect underlying lesion activity and correlate with skeletal outcomes	48 weeks

External Links

•   NIH Clinical Center Detailed Web Page